BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

996 related articles for article (PubMed ID: 17473298)

  • 21. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
    Gong B; Li Z; Yat Wong PC
    J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1415-25. PubMed ID: 26275522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
    Altenberger J; Parissis JT; Costard-Jaeckle A; Winter A; Ebner C; Karavidas A; Sihorsch K; Avgeropoulou E; Weber T; Dimopoulos L; Ulmer H; Poelzl G
    Eur J Heart Fail; 2014 Aug; 16(8):898-906. PubMed ID: 24920349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
    Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
    Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
    Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure].
    Zhang YH; Zhang J; Qing EM; Li H; Sun YX; Zhang L; Bai XJ; Liu WX; Jiang YN; Qu P; Wei BQ; Zhou Q; Huang Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):153-6. PubMed ID: 22490717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hemodynamic and efficacies of domestic levosimendan versus dobutamine in patients with acute decompensated heart failure].
    Zhang YH; Qing EM; Zhang J; Huang Y; Lü R; Zhou Q; Wei BQ; An T; Qing P; Zou CH
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):555-8. PubMed ID: 22490161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
    Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
    Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
    Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
    Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
    Follath F; Cleland JG; Just H; Papp JG; Scholz H; Peuhkurinen K; Harjola VP; Mitrovic V; Abdalla M; Sandell EP; Lehtonen L;
    Lancet; 2002 Jul; 360(9328):196-202. PubMed ID: 12133653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
    Butler J; Giamouzis G; Giannakoulas G
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
    [No Abstract]   [Full Text] [Related]  

  • 34. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
    Cholley B; Caruba T; Grosjean S; Amour J; Ouattara A; Villacorta J; Miguet B; Guinet P; Lévy F; Squara P; Aït Hamou N; Carillion A; Boyer J; Boughenou MF; Rosier S; Robin E; Radutoiu M; Durand M; Guidon C; Desebbe O; Charles-Nelson A; Menasché P; Rozec B; Girard C; Fellahi JL; Pirracchio R; Chatellier G;
    JAMA; 2017 Aug; 318(6):548-556. PubMed ID: 28787507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.